Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions.

Department of Stomatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Anticancer research (Impact Factor: 1.87). 01/2008; 28(6A):3763-9.
Source: PubMed

ABSTRACT The present study aimed at evaluating the clinical importance of Mcm7 and Cdc6 expression in oral squamous cell carcinoma (OSCC) and precancerous lesions.
RT-PCR and immunohistochemistry analysis were performed on 47 frozen samples and 98 paraffin-embedded samples to evaluate the mRNA and protein expressions of Mcm7 and Cdc6.
RT-PCR and immunohistochemistry indicated positive expressions of Mcm7 mRNA and protein in normal oral mucosa, precancerous lesions and OSCC. Significant differences were found between all the groups. Cdc6 mRNA and protein had low expressions in normal oral mucosa but were highly expressed in precancerous lesions and OSCC. Mcm7 and Cdc6 expressions in the lymph node metastasis cases were significantly higher than those of the nonmetastatic carcinomas.
High expressions of Mcm7 and Cdc6 are correlated with the development and metastasis of OSCC and may become a molecular marker for the early diagnosis and prognosis prediction for OSCC.

Download full-text


Available from: Yong-jun Lu, Feb 16, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minichromosome complex maintenance component 7 (MCM7) is a critical component of DNA replication licensing. Amplification and overexpression of MCM7 leads to high rate of prostate cancer metastasis. Recent studies indicate that MCM7 genome encodes a putative 'super-oncogene' cluster including MCM7 oncogene and a miRNA cluster that knocks down the expression of several critical tumor-suppressor genes. In this study, we constructed a vector that constitutively expresses small interference RNA (siRNA) specific for MCM7. Introduction of this vector into prostate cancer cell lines PC3 or Du145 decreases the expression of MCM7 by 80%. The vector inhibits DNA synthesis and generates growth arrest of these cancer cells. Severe combined immunodeficient mice were xenografted PC3 or Du145 tumors, and subsequently treated with this vector through tail vein injection with polyethylenimine. The animals had dramatically smaller tumor volume, less metastasis and better survival rate in comparison with the controls. As a result, intervention of MCM7 expression using siRNA approach may hold the promise for treating androgen refractory prostate cancer.
    Cancer gene therapy 10/2010; 17(10):694-9. DOI:10.1038/cgt.2010.25 · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mantle cell lymphoma and small lymphocytic lymphoma are lymphocyte cancers that have similar morphologies and a common age of onset. Mantle cell lymphoma is generally an aggressive B cell lymphoma with a short median survival time, whereas small lymphocytic lymphoma is typically an indolent B cell lymphoma with a prolonged median survival time. Using primary tumor samples in bi-directional suppression subtractive hybridization, we identified genes with differential expression in an aggressive mantle cell lymphoma versus an indolent small lymphocytic lymphoma. "Virtual" Northern blot analyses of multiple lymphoma samples confirmed that a set of genes was preferentially expressed in aggressive mantle cell lymphoma compared to indolent small lymphocytic lymphoma. These analyses identified mantle cell lymphoma-specific genes that may be involved in the aggressive behavior of mantle cell lymphoma and possibly other aggressive human lymphomas. Interestingly, most of these differentially expressed genes have not been identified using other techniques, highlighting the unique ability of suppression subtractive hybridization to identify potentially rare or low expression genes.
    Acta histochemica 12/2010; 113(7):729-42. DOI:10.1016/j.acthis.2010.11.001 · 1.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The miniature chromosome maintenance (MCM) complex is a group of proteins that are essential for DNA replication licensing and control of cell cycle progression from G1 to S phase. Recent studies suggest that MCM7 is overexpressed and amplified in a variety of human malignancies. MCM7 genome sequence contains a cluster of miRNA that has been shown to downregulate expression of several tumor suppressors including p21, E2F1, BIM and pTEN. The oncogenic potential of MCM7 and its embedded miRNA has been demonstrated vigorously in in vitro experiments and in animal models, and they appear to cooperate in initiation of cancer. MCM7 protein also serves as a critical target for oncogenic signaling pathways such as androgen receptor signaling, or tumor suppressor pathways such as integrin α7 or retinoblastoma signaling. This review analyzes the transforming activity and signaling of MCM7, oncogenic function of miRNA cluster that is embedded in the MCM7 genome, and the potential of gene therapy that targets MCM7.
    02/2011; 2(2):120-4. DOI:10.5306/wjco.v2.i2.120
Show more